

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : C12N 9/20, 15/55, C11D 3/386 C12N 5/14	A1	(11) International Publication Number: WO 92/05249 (43) International Publication Date: 2 April 1992 (02.04.92)
(21) International Application Number: PCT/DK91/00271 (22) International Filing Date: 13 September 1991 (13.09.91) (30) Priority data: 2194/90 13 September 1990 (13.09.90) DK 2195/90 13 September 1990 (13.09.90) DK 2196/90 13 September 1990 (13.09.90) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only) : SVENDSEN, Allan [DK/DK]; Bakkeledet 28, DK-3460 Birkerød (DK). CLAUSEN, Ib, Groth [DK/DK]; Ordrup Jagtvej 153, st.tv., DK-2920 Charlottenlund (DK). PATKAR, Shamkant, Anant [DK/DK]; Christoffers Allé 91, DK-2800 Lyngby (DK). GORMSEN, Erik [DK/DK]; Snekketof-ten 15, DK-2830 Virum (DK).		(74) Common Representative: NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2880 Bagsvaerd (DK). (81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: LIPASE VARIANTS (57) Abstract Lipases comprising a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule, which pocket forms part of and is surrounded by a lipid contact zone, are mutated by deletion or substitution of one or more amino acid residues in the lipid contact zone so as to change the electrostatic charge and/or hydrophobicity of the lipid contact zone or so as to change the surface conformation of the lipid contact zone of the lipases.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

LIPASE VARIANTSFIELD OF INVENTION

5

The present invention relates to novel lipase enzyme variants with improved properties, DNA constructs coding for the expression of said variants, host cells capable of expressing the variants from the DNA constructs, as well as a method of
10 producing the variants by cultivating said host cells.

BACKGROUND OF THE INVENTION

The advent and development of recombinant DNA techniques has had
15 a profound influence on the field of protein chemistry. It has been envisaged that these techniques will make it possible to design peptides and proteins, such as enzymes, in accordance with specific criteria, thus permitting the production of compounds with desired properties.

20

Due to the availability of such techniques, it has become possible to construct enzymes with desired amino acid sequences, and a fair amount of research has been devoted to this object.

25 The primary structure of a number of lipases has been determined and described in the literature (Boel et al., Lipids 23, 701-706 (1988), de Caro et al., Biochim. Biophys. Acta 671, 129-138 (1981), Winkler et al., Nature 343, 771-774 (1990)). Furthermore also the tertiary structure of a more limited number of lipases
30 has been elucidated (Winkler et al., Nature 343, 771-774 (1990), Brady et al., Nature 343, 767-770 (1990) J.D. Schrag et al., Nature 351, 1991, pp. 761-764). From these investigations it appears that lipases seem to have certain structural features in common, but that, on the other hand, major structural variations
35 also exist among the lipases.

SUMMARY OF THE INVENTION

Further investigations have now shown that improved properties of lipases may be obtained by one or more specific mutations in the DNA sequence expressing a specific lipase in order to obtain
5 lipase variants exhibiting such improved properties.

Consequently, in one aspect, the present invention relates to a lipase variant of a parent lipase comprising a trypsin-like catalytic triad including an active serine located in a
10 predominantly hydrophobic, elongated binding pocket of the lipase molecule, wherein the electrostatic charge and/or hydrophobicity of the lipid contact zone of the parent lipase is changed by deleting or substituting one or more negatively charged amino acid residues by neutral or positively charged
15 amino acid residue(s), and/or by substituting one or more neutral amino acid residues by positively charged amino acid residue(s), and/or by deleting or substituting one or more hydrophilic amino acid residues by hydrophobic amino acid residue(s). For the sake of convenience, this lipase variant is
20 termed lipase variant I in the following.

In the present context, the term "trypsin-like" is intended to indicate that the parent lipase comprises a catalytic triad at the active site corresponding to that of trypsin, i.e. the amino
25 acids Ser, His and one of Asp, Glu, Asn or Gln. Some lipases may also comprise a surface loop structure which covers the active serine when the lipase is in inactive form (an example of such a lipase is described by Brady et al., Nature 343, 1990, pp. 767-770). When the lipase is activated, the loop structure is
30 shifted to expose the active site residues, creating a surface with increased surface hydrophobicity which interacts with the lipid substrate at or during hydrolysis. For the present purpose, this surface is termed the "lipid contact zone", intended to include amino acid residues located within or
35 forming part of this surface (or a corresponding surface of lipases which do not comprise such a loop structure). These residues may participate in lipase interaction with the

substrate at or during hydrolysis where the lipase hydrolyses triglycerides from the lipid phase when activated by contact with the lipid surface. During hydrolysis of the triglycerides, fatty acids and mono- and di-glycerides are formed in varying amounts. One reason for changing the electrostatic charge and/or hydrophobicity of the lipid contact zone by mutating the lipase in that zone is that the fatty acids formed during hydrolysis may remain in the lipid phase, thus forming a negatively charged surface. When the lipase is used for washing purposes, negatively charged detergents may form negative charges on the lipid surface. Thus, by preparing lipase variants which are less negatively charged and/or more hydrophobic, it may be possible to obtain lipases with different specificities and/or improved properties.

In another aspect, the present invention relates to a lipase variant comprising a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule, said lipase variant being further characterized by substitution, deletion, or insertion of one or more amino acid residues at the position of one or more of the amino acid residues constituting the sequence of the lipid contact zone comprising residues located within the part of the lipase structure containing the active serine residue, which residues participate in the interaction with the substrate at or during hydrolysis so as to change the surface conformation of said lipid contact zone. The purpose of such a surface modification of the lipase molecule is to provide improved accessibility of the active site of the lipase to a lipid substrate. For the sake of convenience, this lipase variant is termed lipase variant II in the following.

In a still further aspect, the invention relates to a lipase variant of a type comprising (i) a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule and (ii) a surface loop structure which covers the active serine

when the lipase is in inactive form and which changes its conformation when the lipase is activated so as to make the active serine accessible to a lipid substrate, the loop structure having a predominantly hydrophobic inner surface facing the binding pocket and a predominantly hydrophilic outer surface, said lipase variant being characterized by substitution, deletion or insertion of one or more amino acid residues at the position of one or more of the amino acid residues constituting the sequence of the loop structure and/or constituting the sequence of the lipid contact zone comprising residues located within the part of the lipase structure containing the active serine residue, which residues participate in either shifting the surface loop structure or the interaction with the substrate at or during hydrolysis. This will cause the loop structure to become more open whereby the active serine becomes more accessible to the substrate. For the sake of convenience, this lipase variant is termed lipase variant III in the following.

The present invention also relates to a DNA construct comprising a DNA sequence encoding a lipase variant as indicated above, a recombinant expression vector carrying said DNA construct, a cell transformed with the DNA construct or the expression vector, as well as a method of producing a lipase variant of the invention by culturing or growing said cell under conditions conducive to the production of the lipase variant, after which the lipase variant is recovered from the culture.

The invention further relates to a detergent additive comprising a lipase variant of the invention, optionally in the form of a non-dusting granulate, stabilised liquid or protected enzyme, as well as to a detergent composition comprising lipase variant of the invention.

DETAILED DISCLOSURE OF THE INVENTION

In the present description and claims, the following abbreviations are used:

5 Amino acids:

	A	=	Ala	=	Alanine
	V	=	Val	=	Valine
	L	=	Leu	=	Leucine
10	I	=	Ile	=	Isoleucine
	P	=	Pro	=	Proline
	F	=	Phe	=	Phenylalanine
	W	=	Trp	=	Tryptophan
	M	=	Met	=	Methionine
15	G	=	Gly	=	Glycine
	S	=	Ser	=	Serine
	T	=	Thr	=	Threonine
	C	=	Cys	=	Cysteine
	Y	=	Tyr	=	Tyrosine
20	N	=	Asn	=	Asparagine
	Q	=	Gln	=	Glutamine
	D	=	Asp	=	Aspartic Acid
	E	=	Glu	=	Glutamic Acid
	K	=	Lys	=	Lysine
25	R	=	Arg	=	Arginine
	H	=	His	=	Histidine

In describing lipase variants according to the invention, the following nomenclature is used for ease of reference:

30 Original amino acid(s):position(s):substituted amino acid(s)

According to this nomenclature, for instance the substitution of glutamic acid for glycine in position 195 is shown as:

Gly 195 Glu or G195E

35 a deletion of glycine in the same position is shown as:

Gly 195 * or G195*

and insertion of an additional amino acid residue such as lysine is shown as:

Gly 195 GlyLys or G195GK

- 5 Where a specific lipase contains a "deletion" in comparison with other lipases and an insertion is made in such a position this is indicated as:

* 36 Asp or *36D

for insertion of an aspartic acid in position 36

10

Multiple mutations are separated by pluses, i.e.:

Arg 170 Tyr + Gly 195 Glu or R170Y+G195E

representing mutations in positions 170 and 195 substituting tyrosine and glutamic acid for arginine and glycine, respectively.

15

According to the invention, lipase variant I is preferably one in which one or more glutamic acid or aspartic acid residues of the lipid contact zone of the lipase are substituted by glutamine, asparagine, alanine, leucine, valine, serine, threonine, lysine, or arginine.

20

Although the parent lipase may be derived from a variety of sources such as mammalian lipases, e.g. pancreatic, gastric, hepatic or lipoprotein lipases, it is generally preferred that it is a microbial lipase. As such, the parent lipase may be selected from yeast, e.g. Candida, lipases, bacterial, e.g. Pseudomonas, lipases or fungal, e.g. Humicola or Rhizomucor lipases. It is particularly preferred to select the parent lipase from a group of structurally homologous lipases.

25

30

In a preferred embodiment of lipase variant I of the invention, the parent lipase is a Rhizomucor miehei lipase, in particular the lipase described in EP 305 216. In this embodiment, one or more negatively charged amino acid residues may be substituted by one or more positively charged or neutral amino acid residues as follows

35

5
D91N, K, R, A, V, L, S, T;
D256N, K, R, A, V, L, S, T;
D226N, K, R, A, V, L, S, T;
D61N, K, R, A, V, L, S, T;
D113N, K, R, A, V, L, S, T;
E201Q, K, R, A, V, L, S, T;
D243N, K, R, A, V, L, S, T.

10 In another preferred embodiment of lipase variant I of the invention, the parent lipase is a Humicola lanuginosa lipase, in particular the lipase produced by H. lanuginosa strain DSM 4106 (cf. EP 258 068). In this embodiment, one or more negatively charged amino acid residues may be substituted by one or more neutral or positively charged amino acid residues as follows:

15 E87Q, K, R, A, N, T, S, L, V;
D254N, K, R, A, Q, T, S, L, V;
D242N, K, R, A, Q, T, S, L, V;
E210Q, K, R, A, N, T, S, L, V;
E56Q, K, R, A, N, T, S, L, V;
20 D96N, K, R, A, Q, T, S, L, V;
D111N, K, R, A, Q, T, S, L, V;
D62A, Q, N, T, S, K, R, L, V;
E219A, Q, N, T, S, K, R, L, V;
E234A, Q, N, T, S, K, R, L, V;
25 E57A, Q, N, T, S, K, R, L, V;
E99A, Q, N, T, S, K, R, L, V;
D27A, Q, N, T, S, K, R, L, V; or
E239A, Q, N, T, S, K, R, L, V.

30 Particularly preferred substitutions according to the invention are

E87Q + D254N + D242N + E210Q;
E87Q + D254N + E210Q;
D96N + E87Q + D254N;
35 R209A + E210A.

Alternatively, one or more neutral amino acid residues may be substituted by one or more positively charged amino acid residues as follows:

5 T267K,R;
 S85K,R;
 T226K,R;
 N88K,R;
 N92K,R;
 I255K,R;
10 I202K,R
 L206K,R;
 L259K,R;
 V203K,R; or
 L227K,R

15

It should be noted that the Humicola lanuginosa lipase and the Rhizomucor miehei lipase belong to the same group of lipases. This implies that the overall three-dimensional structure of the two lipases is very similar and has been shown by X-ray
20 crystallography to be highly homologous (a computer model of the H. lanuginosa and the Rh. miehei lipase is shown in Figs. 1A and B and 2A and B, respectively, from which the similarities between the lipid contact zones of the two lipases are clearly apparent). It is therefore probable that modifications of the
25 type indicated for either lipase will also be functional for the other lipase.

In one embodiment of lipase variant II, one or more amino acid residues may be substituted by one or more other, less bulky
30 amino acid residues. The purpose of such modification is to expose the active site of the lipase, thus making it more available for contact with the substrate. In particular, the less bulky amino acid residues may be selected from valine, threonine, serine, glycine or alanine.

35

Although the parent lipase of lipase variant II may be derived from a variety of sources such as mammalian lipases, e.g.

pancreatic, gastric, hepatic or lipoprotein lipases, it is generally preferred that it is a microbial lipase. As such, the parent lipase may be selected from yeast, e.g. Candida, lipases, bacterial, e.g. Pseudomonas, lipases or fungal, e.g. Humicola or
5 Rhizomucor, lipases.

For instance, when the parent lipase is the Rhizomucor miehei lipase mentioned above, the following substitutions may preferably be made

10 I204V,A,T,S,G;
L208V,A,T,S,G;
F213V,A,T,S,G; or
I254V,A,T,S,G.

15 When the parent lipase is the Humicola lanuginosa lipase mentioned above, the following substitutions may preferably be made

I202V,A,T,S,G;
L206V,A,T,S,G;
20 F211V,A,T,S,G,I; or
I255V,A,T,S,G.

When lipase variant II is one provided with one or more surface loop sequences, one or more amino acid residues forming part of
25 the loop sequence may advantageously be deleted. The purpose of such a modification is to improve the accessibility of the active serine to the substrate.

To this end, it has been found convenient to delete 2-8, in particular 2-6 amino acid residues from the loop sequence. For
30 instance, when the parent lipase is the Rhizomucor miehei lipase mentioned above, one or more amino acid residues may be deleted at one or more of the following positions: 82-113, 211-215, 235-243, 245-269 or 264-269. Specific examples of suitable deletions
35 (and, in the case of the first example mentioned, substitution) are as follows

N264* + T265* + G266* + L267* + C268* + T269* + C22T;

F213* + F215*;
D238* + L239* + E240* + D243*; or
S247* + F251* + T252*.

5 When the parent lipase is the Humicola lanuginosa lipase mentioned above, one or more amino acid residues may be deleted at one or more of the following positions: 84-112, 209-213, 238-245, 247-254 or 264-269. Specific examples of suitable deletions (and, in the case of the first example mentioned, substitution)
10 are as follows

L264* + I265* + G266* + T267* + C268* + L269* + C22T;
R209* + E210*;
F211* + Y213*;
D242* + E239* + I241; or
15 N247* + D254*.

In a particular embodiment of lipase variant II, the parent lipase comprises a surface loop structure which covers the active serine when the lipase is in inactive form and which
20 changes its conformation when the lipase is activated so as to make the active serine accessible to a lipid substrate. This loop structure has a predominantly hydrophobic inner surface facing the binding pocket and a predominantly hydrophilic outer surface. This lipase variant is characterized by deletion of one
25 or more amino acid residues of the sequence composing the loop structure. The loop structure corresponds to the one described for human pancreatic lipase (cf. Winkler et al., Nature 343, 1990, pp. 771-774) and for Rhizomucor miehei lipase (cf. Brady et al., Nature 343, 1990, pp. 767-770). However, the lipase
30 variant preferably has a shorter loop structure comprising no less than 5 amino acid residues. The loop structure may additionally comprise substitution of one or more amino acid residues. There is some indication, however, that the tryptophan residue present in the loop structure (W89 of the H. lanuginosa
35 lipase and W88 of the Rh. miehei lipase) should be conserved.

In lipase variant III, at least one amino acid residue of the loop structure is preferably substituted by cysteine, and at least one other amino acid residue is preferably also substituted by cysteine, the two cysteine residues being so positioned relative to each other that they form a disulphide bond. This will cause the surface loop structure to shift so that it becomes more open whereby the active serine becomes more accessible to the substrate.

10 For instance, when the parent lipase is the Rhizomucor miehei lipase mentioned above, the following substitutions may be made

S114C + A90C;
R86C + D61C;
S84C + D61C;
15 N87C + D61C;
Y60C + R78C; or
Y60C + N87C.

When, on the other hand, the parent lipase is the Humicola lanuginosa lipase mentioned above, the following substitutions may be made

G61C + N88C;
G61C + E87C;
D62C + E87C;
25 D62C + S85C;
D62C + N88C; or
S116C + G91C.

Alternatively, a more open conformation of the loop structure in an aqueous medium may be obtained by substituting one or more hydrophilic amino acid residues by one or more less hydrophilic amino acid residues of the binding pocket in which the catalytic triad, including the active serine, is located.

35 For instance, when the parent lipase is the Rhizomucor miehei lipase mentioned above, the following substitutions may be made

I204V,A,T,S,G;

12

L208V,A,T,S,G;
F213V,A,T,S,G;
I254V,A,T,S,G;
L255V,A,T,S,G;
5 L258V,A,T,S,G;
L267V,A,T,S,G; or
F94L,T,K.

In particular, the amino acid substitutions may be combined as
10 follows

I204T + L255T + L267T; or
L208T + I254T + L258T.

When the parent lipase is the Humicola lanuginosa lipase
15 mentioned above, the following substitutions may be made

L93V,T,S,A,G;
I90V,T,S,A,G;
I86V,T,S,A,G;
I202V,T,S,A,G;
20 L206V,T,S,A,G;
I255V,T,S,A,G;
L259V,T,S,A,G;
F95L,T,K; or
F211L,T,K.

25

In preferred embodiments of lipase variant IV, one or more amino
acid residues may be substituted as follows:

F95K;
I86T;
30 I90T;
I255T;
L259T;
L206T; or
L206T + I255T + L259T

35

It should be noted that, according to the invention, any one of
the modifications of the amino acid sequence indicated above for

the lipase variants I-III may be combined with any one of the other modifications mentioned above.

Methods of preparing lipase variants of the invention

5

Several methods for introducing mutations into genes are known in the art. After a brief discussion of cloning lipase-encoding DNA sequences, methods for generating mutations at specific sites within the lipase-encoding sequence will be discussed.

10

Cloning a DNA sequence encoding a lipase

The DNA sequence encoding a parent lipase may be isolated from any cell or microorganism producing the lipase in question by various methods, well known in the art. First a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the lipase to be studied. Then, if the amino acid sequence of the lipase is known, homologous, labelled oligonucleotide probes may be synthesized and used to identify lipase-encoding clones from a genomic library of bacterial DNA, or from a fungal cDNA library. Alternatively, a labelled oligonucleotide probe containing sequences homologous to lipase from another strain of bacteria or fungus could be used as a probe to identify lipase-encoding clones, using hybridization and washing conditions of lower stringency.

Yet another method for identifying lipase-producing clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming lipase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for lipase. Those bacteria containing lipase-bearing plasmid will produce colonies surrounded by a halo of clear agar, due to digestion of the substrate by secreted lipase.

Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters **22**, 1981, pp. 1859-1869, or the
5 method described by Matthes et al., The EMBO J. **3**, 1984, pp. 801-805. According to the phosphoramidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

10

Finally, the DNA sequence may be of mixed genomic and synthetic, mixed synthetic and cDNA or mixed genomic and cDNA origin prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate), the fragments corresponding to various
15 parts of the entire DNA sequence, in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al., Science **239**, 1988, pp. 487-491.

20

Site-directed mutagenesis of the lipase-encoding sequence

Once a lipase-encoding DNA sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides
25 contain nucleotide sequences flanking the desired mutation sites; mutant nucleotides are inserted during oligonucleotide synthesis. In a specific method, a single-stranded gap of DNA, bridging the lipase-encoding sequence, is created in a vector carrying the lipase gene. Then the synthetic nucleotide, bearing
30 the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described
35 in Morinaga et al., (1984, *Biotechnology* **2**:646-639). U.S. Patent number 4,760,025, by Estell et al., issued July 26, 1988, discloses the introduction of oligonucleotides encoding multiple

mutations by performing minor alterations of the cassette, however, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

5

Another method of introducing mutations into lipase-encoding sequences is described in Nelson and Long, Analytical Biochemistry 180, 1989, pp. 147-151. It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid (see also Figs. 3 and 4 where this method is further outlined).

10
15

Expression of lipase variants

According to the invention, a mutated lipase-coding sequence produced by methods described above, or any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes. To permit the secretion of the expressed protein, nucleotides encoding a "signal sequence" may be inserted prior to the lipase-coding sequence. For expression under the direction of control sequences, a target gene to be treated according to the invention is operably linked to the control sequences in the proper reading frame. Promoter sequences that can be incorporated into plasmid vectors, and which can support the transcription of the mutant lipase gene, include but are not limited to the prokaryotic β -lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731) and the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25). Further references can

20

25

30

35

also be found in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94.

According to one embodiment B. subtilis is transformed by an
5 expression vector carrying the mutated DNA. If expression is to
take place in a secreting microorganism such as B. subtilis a
signal sequence may follow the translation initiation signal and
precede the DNA sequence of interest. The signal sequence acts
10 to transport the expression product to the cell wall where it is
cleaved from the product upon secretion. The term "control
sequences" as defined above is intended to include a signal
sequence, when is present.

In a currently preferred method of producing lipase variants of
15 the invention, a filamentous fungus is used as the host
organism. The filamentous fungus host organism may conveniently
be one which has previously been used as a host for producing
recombinant proteins, e.g. a strain of Aspergillus sp., such as
A. niger, A. nidulans or A. oryzae. The use of A. oryzae in the
20 production of recombinant proteins is extensively described in,
e.g. EP 238 023.

For expression of lipase variants in Aspergillus, the DNA
sequence coding for the lipase variant is preceded by a
25 promoter. The promoter may be any DNA sequence exhibiting a
strong transcriptional activity in Aspergillus and may be
derived from a gene encoding an extracellular or intracellular
protein such as an amylase, a glucoamylase, a protease, a
lipase, a cellulase or a glycolytic enzyme.

30 Examples of suitable promoters are those derived from the gene
encoding A. oryzae TAKA amylase, Rhizomucor miehei aspartic
proteinase, A. niger neutral α -amylase, A. niger acid stable α -
amylase, A. niger glucoamylase, Rhizomucor miehei lipase, A.
35 oryzae alkaline protease or A. oryzae triose phosphate
isomerase.

In particular when the host organism is A. oryzae, a preferred promoter for use in the process of the present invention is the A. oryzae TAKA amylase promoter as it exhibits a strong transcriptional activity in A. oryzae. The sequence of the TAKA
5 amylase promoter appears from EP 238 023.

Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter.

10 The techniques used to transform a fungal host cell may suitably be as described in EP 238 023.

To ensure secretion of the lipase variant from the host cell, the DNA sequence encoding the lipase variant may be preceded by
15 a signal sequence which may be a naturally occurring signal sequence or a functional part thereof or a synthetic sequence providing secretion of the protein from the cell. In particular, the signal sequence may be derived from a gene encoding an Aspergillus sp. amylase or glucoamylase, a gene encoding a
20 Rhizomucor miehei lipase or protease, or a gene encoding a Humicola cellulase, xylanase or lipase. The signal sequence is preferably derived from the gene encoding A. oryzae TAKA amylase, A. niger neutral α -amylase, A. niger acid-stable α -amylase or A. niger glucoamylase.

25

The medium used to culture the transformed host cells may be any conventional medium suitable for growing Aspergillus cells. The transformants are usually stable and may be cultured in the absence of selection pressure. However, if the transformants are
30 found to be unstable, a selection marker introduced into the cells may be used for selection.

The mature lipase protein secreted from the host cells may conveniently be recovered from the culture medium by well-known
35 procedures including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium

sulphate, followed by chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

The present invention also relates to a detergent additive comprising a lipase variant according to the invention, preferably in the form of a non-dusting granulate, stabilized liquid or protected enzyme. Non-dusting granulates may be produced e.g. according to US 4,106,991 and 4,661,452 (both to Novo Industri A/S) and may optionally be coated by methods known in the art. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238 216.

The detergent additive may suitably contain 0.02-200 mg of enzyme protein per gram of the additive. It will be understood that the detergent additive may further include one or more other enzymes, such as a protease, cellulase, peroxidase or amylase, conventionally included in detergent additives.

In a still further aspect, the invention relates to a detergent composition comprising a lipase variant of the invention. Detergent compositions of the invention additionally comprise surfactants which may be of the anionic, non-ionic, cationic, amphoteric, or zwitterionic type as well as mixtures of these surfactant classes. Typical examples of suitable surfactants are linear alkyl benzene sulfonates (LAS), alpha olefin sulfonates (AOS), alcohol ethoxy sulfates (AEOS), alcohol ethoxylates (AEO), alkyl sulphates (AS), alkyl polyglycosides (APG) and alkali metal salts of natural fatty acids.

Detergent compositions of the invention may contain other detergent ingredients known in the art as e.g. builders, bleaching agents, bleach activators, anti-corrosion agents, sequestering

agents, anti soil-redeposition agents, perfumes, enzyme stabilizers, etc.

The detergent composition of the invention may be formulated in any convenient form, e.g. as a powder or liquid. The enzyme may be stabilized in a liquid detergent by inclusion of enzyme stabilizers as indicated above. Usually, the pH of a solution of the detergent composition of the invention will be 7-12 and in some instances 7.0-10.5. Other detergent enzymes such as proteases, cellulases, peroxidases or amylases may be included the detergent compositions of the invention, either separately or in a combined additive as described above.

BRIEF DESCRIPTION OF THE DRAWINGS

15

The present invention is described in the following with reference to the appended drawings, in which

Fig. 1A and B are computer models showing the three-dimensional structure of the lipid contact zone of the H. lanuginosa lipase when the lipase is in inactive (A) and active (B) form, respectively. "White" residues represent hydrophobic amino acids (Ala, Val, Leu, Ile, Pro, Phe, Trp, Gly and Met), "yellow" residues represent hydrophilic amino acids (Thr, Ser, Gln, Asn, Tyr and Cys), "blue" residues represent positively charged amino acids (Lys, Arg and His), and "red" residues represent negatively charged amino acids (Glu and Asp);

Fig. 2A and 2B are computer models showing the three-dimensional structure of the lipid contact zone of the Rh. miehei lipase when the lipase is in inactive (A) and active (B) form, respectively. "White" residues represent hydrophobic amino acids (Ala, Val, Leu, Ile, Pro, Phe, Trp, Gly and Met), "yellow" residues represent hydrophilic amino acids (Thr, Ser, Gln, Asn, Tyr and Cys), "blue" residues represent positively charged amino acids (Lys, Arg and His), and "red" residues represent negatively charged amino acids (Glu and Asp);

Fig. 3 is a schematic representation of the preparation of plasmids encoding lipase variants by polymerase chain reaction (PCR);

5 Fig. 4 is a schematic representation of the three-step mutagenesis by PCR;

Fig. 5 shows a restriction map of plasmid pAO1;

10 Fig. 6 shows a restriction map of plasmid pAHL; and

Fig. 7 shows a restriction map of plasmid pARML.

The present invention is further illustrated in the following
15 examples which are not in any way intended to limit the scope of the invention as claimed.

GENERAL METHODS

20 Expression of *Humicola lanuginosa* lipase and *Rhizomucor miehei* lipase in *Aspergillus oryzae*:

Cloning of *Humicola lanuginosa* lipase and *Rhizomucor miehei* lipase is described in EP 305,216 and EP 238 023, respectively.

25 These patent applications also describe expression and characterization of the two lipases in *Aspergillus oryzae*. The two expression plasmids used are termed p960 (carrying the *H. lanuginosa* lipase gene) and p787 (carrying the *R. miehei* lipase gene).

30

The expression plasmids used in this application are identical to p787 and p960, except for minor modifications immediately 3' to the lipase coding regions. The modifications were made in the following way: p960 was digested with NruI and BamHI restriction
35 enzymes. Between these two sites the BamHI/NheI fragment from plasmid pBR322, in which the NheI fragment was filled in with Klenow polymerase, was cloned, thereby creating plasmid pAO1

(Fig. 5) which contains unique BamHI and NheI sites. Between these unique sites BamHI/XbaI fragments from p960 and p787 were cloned to give pAHL (Fig. 6) and pARML (Fig. 7), respectively.

5 Site-directed in vitro mutagenesis of lipase genes:

Three different approaches were used for introducing mutations into the lipase genes.

- 10 One method employed was oligonucleotide site-directed mutagenesis which is described by Zoller & Smith, DNA, Vol. 3, No. 6, 479-488 (1984). The method is briefly described in the following, and is described thoroughly in example 1.
- 15 Isolated from the expression plasmid, the lipase gene of interest is inserted into a circular M13 bacteriophage vector. To the single-stranded genome, a chemically synthesized complementary DNA-strand is annealed. This DNA-strand contains the mutation to be introduced flanked by sequences complementary
- 20 to lipase sequences on the circular DNA. In vitro, the primer is then extended in the entire length of the circular genome biochemically using Klenow polymerase. When transformed in E.coli, the heteroduplex will give rise to double-stranded DNA with the desired sequence from which a fragment can be isolated
- 25 and re-inserted into the expression plasmid.

- Another method employed is described in Nelson & Long, Analytical Biochemistry, 180, 147-151 (1989). It involves the 3-step generation of a PCR (polymerase chain reaction) fragment
- 30 containing the desired mutation introduced by using a chemically synthesized DNA-strand as one of the primers in the PCR-reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation can be isolated by cleavage with restriction enzymes and re-inserted into the expression plasmid.
 - 35 This method is thoroughly described in example 3. In figures 3 and 4 the method is further outlined.

In a further method, usually termed "cassette mutagenesis", a segment between two restriction sites of the lipase-encoding region is replaced by a synthetic DNA fragment carrying the desired mutation.

5

Lipase Variants I

Example 1: Construction of a plasmid expressing the D96L variant of Humicola lanuginosa lipase.

10

Isolation of the lipase gene:

The expression plasmid p960 contains the coding region for Humicola lanuginosa lipase on a BamHI/XbaI restriction fragment
15 (the DNA and amino acid sequence of the lipase are shown in the appended Sequence Listing ID No. 1). The BamHI/XbaI fragment was isolated as follows: The expression plasmid was incubated with the restriction endonucleases BamHI and XbaI. The conditions were: 5 μ g plasmid, 10 units of BamHI, 10 units of XbaI, 100 mM
20 NaCl, 50 mM Tris-HCl, pH 7.5, 10 mM MgCl₂ and 1 mM DTT in 50 μ l volume. The temperature was 37°C and the reaction time 2 hours. The two fragments were separated on a 1% agarose gel and the desired fragment was isolated from the gel.

Ligation to the vector M13mp18:

The bacteriophage vector M13mp18 on its double-stranded, replicative form was digested with BamHI and XbaI under conditions as described above. The isolated restriction fragment
30 was ligated to the digested bacteriophage vector in the following reaction mixture: Fragment 0.2 μ g, vector 0.02 μ g, 50 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, 10 mM DTT and 1 mM ATP in a 20 μ l volume at 16°C for 3 hours. 5 μ l of this mixture was transformed into the E.coli strain JM101. The presence of
35 fragment in the vector was identified by restriction enzyme analysis on double-stranded M13-DNA isolated from the transformants.

Isolation of single-stranded (ss) DNA (template):

From the transformant described above, ss-DNA was isolated according to a method described by Messing in Gene, 19, 269-276
5 (1982).

5' phosphorylation of the mutagenisation primer:

The mutagenisation primer with the sequence
10 5'-TTTCTTTCAACAAGAAGTTAAGA-3' was phosphorylated at the 5' end in a 30 μ l reaction mixture containing 70 mM Tris-HCl, pH 7.0, 10 mM MgCl₂, 5 mM DTT, 1 mM ATP, 100 pmol oligonucleotide and 3.6 units of T4 polynucleotide kinase. The reaction was carried out for 30 min. at 37°C. Then, the enzyme was inactivated by
15 incubating the mixture for 10 min. at 65°C.

Annealing of template and phosphorylated mutagenisation primer:

Annealing of template and primer was carried out in a 10 μ l
20 volume containing 0.5 pmol template, 5 pmol primer, 20 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 50 mM NaCl and 1 mM DTT by heating for 10 min. at 65°C and cooling afterwards to 0°C.

Extension/ligation reaction:

25 To the reaction mixture above, 10 μ l of the following mixture was added: 0.3 mM dATP, 0.3 mM dCTP, 0.3 mM dGTP, 0.3 mM TTP, 1 mM ATP, 20 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 10 mM DTT, 3 units of T4 DNA ligase and 2.5 units of Klenow polymerase. Then, the
30 reaction was carried out for 16 hours at 16°C.

Transformation of JM101:

The reaction mixture above was transformed in different
35 dilutions into CaCl₂-treated E.coli JM101 cells using standard techniques and plated in 2 x YT top agar on 2 x YT agar plates. (2 x YT = tryptone 16 g/l, yeast extract 10 g/l, NaCl 5 g/l. 2

x YT topagar = 2 x YT with 0.4% agarose added and autoclaved. 2
x YT agar plates = 2 x YT with 2% agar added and autoclaved).
The plates were incubated at 37°C overnight.

5 Identification of positive clones:

The method used was plaque-lift hybridization which is described
in the following: a nitrocellulose filter was placed on a plate
with a suitable plaque-density, so that the filter was wetted.
10 The filter was then bathed in the following solutions: 1.5 M
NaCl, 0.5 M NaOH for 30 sec., 1.5 M NaCl, 0.5 M Tris-HCl, pH 8.0
for 1 min. and 2 x SSC (0.3 M NaCl, 0.03 M sodium citrate) till
later use. The filter was dried on 3MM filter paper and baked
for 2 hours at 80°C in a vacuum oven.

15

The mutagenisation primer with the sequence
5'-TTTCTTTCAACAAGAAGTTAAGA-3' was labelled radioactively at the
5'-end in a 30 µl volume containing 70 mM Tris-HCl, pH 7.5, 10
mM MgCl₂, 5 mM DTT, 10 pmol oligonucleotide, 20 pmol γ-32P-ATP
20 and 3.5 units of T4 polynucleotide kinase. The mixture was
incubated at 37°C for 30 min. and then for 5 min. at 100°C.

The dried filter was prehybridised for 2 hours at 65°C in 6 x
SSC, 0.2% bovine serum albumin, 0.2% Ficoll, 0.2%
25 polyvinylpyrrolidone, 0.2% sodium-dodecyl-sulphate (SDS) and 50
µg/ml sonicated salmon sperm DNA. Then, the reaction mixture
containing the labelled probe was added to 15 ml of fresh
pre-hybridization mix, and the filter was bathed herein
overnight at 27°C with gentle shaking. After hybridisation, the
30 filter was washed 3 times each 15 min. in 2 x SSC, 0.1% SDS and
autoradiographed. After wash in the same solution, but now at
50°C, and another autoradiography, plaques containing
DNA-sequences complementary to the mutagenisation primer were
identified.

35

Because the identified clone is a result of a heteroduplex, the plaque was plated again. The hybridisation and identification steps were repeated.

5 Purification of double-stranded M13-phage DNA:

A re-screened clone was used for infection of E.coli strain JM101. A culture containing approximately 10^8 phages and 5 colonies of JM101 was grown for 5 hours in 5 ml 2 x YT medium at 37°C. Then, double-stranded, circular DNA was purified from the pellet according to a method described by Birnboim & Doly, Nucleic Acids Res., 2, 1513 (1979).

Isolation of a restriction fragment encoding modified lipase:

15

The DNA preparation (appr. 5 μ g) isolated above was digested with 10 units of each of the restriction endonucleases BamHI and XbaI in 60 μ l of 100 mM NaCl, 50 mM Tris-HCl, pH 7.5, 10 mM MgCl₂ and 10 mM DTT for 2 hours at 37°C. The DNA products were separated on an agarose gel and the fragment was purified from the gel.

Ligation to the Aspergillus expression vector pAO1 (figure 5):

25 The isolated restriction fragment was ligated to the Aspergillus vector pAO1 digested with the restriction enzymes BamHI and NheI in the following reaction mixture: Fragment 0.2 μ g, vector 0.02 μ g, 50 mM Tris-HCl, pH 7.4, 10 mM MgCl₂, 10 mM DTT, 1 mM ATP in a total volume of 20 μ l. 5 μ l of this reaction mix was used for transformation of E.coli strain MC1061, in which the modified expression plasmid was identified and propagated. The plasmid was called pAHL96L and is identical to pAHL except for the modified codon.

Sequence verification of pAHL96L:

The mutagenized plasmid was sequenced directly on the double-stranded plasmid using the dideoxy chain termination method originally described by Sanger.

Example 2: Construction of plasmids expressing other variants of Humicola lipase.

10

Other mutant lipase genes were constructed using the same method as described in example 1. Plasmid names and primers used for the modifications are listed below.

15	Plasmid name	Primer sequence
	pAHL96N	5'-TCTTTCAAGTTGAAGTTAAGA-3'
	pAHL111N	5'-GTGAAGCCGTTATGTCCCCTG-3'
	pAHL87Q	5'-CGATCCAGTTTTTGTATGGAACGA-3'
	pAHLR209A/E210A	5'-GCTGTAACCGAAAGCAGCCGGCGGGAGTCT-3'
20	pAHL87A	5'-CGATCCAGTTAGCTATGGAACG-3'
	pAHL56A	5'-CTCCAGAGTCAGCAAACGAGTA-3'
	pAHL56Q	5'-CCAGAGTCTTGAAACGAGTAG-3'
	pAHL111L	5'-AAGTGAAGCCCAAATGTCCCCTG-3'
	pAHL210A	5'-TGTAACCGAAAGCGCGGCGGG-3'
25	pAHL210Q	5'-TAACCGAATTGGCGGCGGG-3'
	pAHLR209A	5'-AACCGAATTCAGCCGGCGGGAGT-3'

Example 3: Construction of a plasmid expressing the D254N variant of Humicola lanuginosa lipase.

30

Linearization of plasmid pAHL:

The circular plasmid pAHL was linearized with the restriction enzyme SphI in the following 50 µl reaction mixture: 50 mM NaCl, 10 mM Tris-HCl, pH 7.9, 10 mM MgCl₂, 1 mM dithiothreitol, 1 µg plasmid and 2 units of SphI. The digestion was carried out for 2 hours at 37°C. The reaction mixture was extracted with phenol

(equilibrated with Tris-HCl, pH 7.5) and precipitated by adding 2 volumes of ice-cold 96% ethanol. After centrifugation and drying of the pellet, the linearized DNA was dissolved in 50 μ l H₂O and the concentration estimated on an agarose gel.

5

3-step PCR mutagenesis:

As shown in Fig. 4, 3-step mutagenisation involves the use of four primers:

10

Mutagenisation primer (=A):

5'-GTGCGCAGGGATGTTTCGGAATGTTAGG-3'

PCR Helper 1 (=B):

15

5'-GGTCATCCAGTCACTGAGACCCTCTACCTATTAAATCGGC-3'

PCR Helper 2 (=C): 5'-CCATGGCTTTCACGGTGTCT-3'

PCR Handle (=D): 5'-GGTCATCCAGTCACTGAGAC-3'

20 All 3 steps were carried out in the following buffer containing:
10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin,
0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM TTP, 2.5 units Taq
polymerase.

25 In step 1, 100 pmol primer A, 100 pmol primer B and 1 fmol
linearized plasmid was added to a total of 100 μ l reaction
mixture and 15 cycles consisting of 2 minutes at 95°C, 2 minutes
at 37°C and 3 minutes at 72°C were carried out.

30 The concentration of the PCR product was estimated on an agarose
gel. Then, step 2 was carried out. 0.6 pmol step 1 product and
1 fmol linearized plasmid was contained in a total of 100 μ l of
the previously mentioned buffer and 1 cycle consisting of 5
minutes at 95°C, 2 minutes at 37°C and 10 minutes at 72°C was
35 carried out.

To the step 2 reaction mixture, 100 pmol primer C and 100 pmol primer D was added (1 μ l of each) and 20 cycles consisting of 2 minutes at 95°C, 2 minutes at 37°C and 3 minutes at 72°C were carried out. This manipulation comprised step 3 in the
5 mutagenisation procedure.

Isolation of mutated restriction fragment:

The product from step 3 was isolated from an agarose gel and
10 re-dissolved in 20 μ l H₂O. Then, it was digested with the restriction enzyme BspMII in a total volume of 50 μ l with the following composition: 100 mM NaCl, 50 mM Tris-HCl, pH 7.9, 10 mM MgCl₂, 1 mM DTT and 10 units of BspMII. Incubation was at 37°C for 2 hours. The 264 bp BspMIII fragment was isolated from an
15 agarose gel.

Ligation to expression vector pAHL:

The expression plasmid pAHL was cleaved with BspMII under
20 conditions indicated above and the large fragment was isolated from an agarose gel. To this vector, the mutated fragment isolated above was ligated and the ligation mix was used to transform E.coli. The presence and orientation of the fragment was verified by cleavage of a plasmid preparation from a
25 transformant with restriction enzymes. Sequence analysis was carried out on the double-stranded plasmid using the di-deoxy chain termination procedure developed by Sanger. The plasmid was named pAHL254N and is identical to pAHL, except for the altered codon.

30

Example 4: Construction of plasmids expressing other variants of Humicola lipase.

The following mutants were constructed using the same method as
35 described in example 3, except other restriction enzymes were used for digesting the PCR-product and the vector used for

recloning of the mutated fragment. Plasmid names and primers used for the modifications are listed below.

	Plasmid name	Primer A sequence
5	pAHL254K	5'-GTGCGCAGGGATCTTCGGAATGTT-3'
	pAHL254R	5'-GTGCGCAGGGATTCTCGGAATGTT-3'
	pAHL242N	5'-GCCGCCGGTGGCGTTGATGCCTTCTAT-3'
	pAHL242N/D254N	5'GTGCGCAGGGATGTTTCGGAATGTTAGGCTGGTTATTGC CGCCGGTGGCGTTGATGCCTTCTAT-3'
10	pAHL87R	5'-CCCGATCCAGTTTCTTATCGATCGAGAGCCGCGG-3'
	pAHL87K	5'-CGATCCAGTTCTTTATCGATCGAGAGCCACGG-3'

Example 5: Construction of lipase variants by combination of available mutants:

15

The following mutants were constructed by combining plasmid fragments of mutants constructed above. For example, pAHL87K/D254K was constructed by isolating the BamHI/BstXI restriction fragment from pAHL87K and inserting the fragment

20 into pAHL254K digested with BamHI and BstXI:

Plasmid

pAHL87K/D254K

pAHL87Q/D254N/D242N/E210Q

pAHL87Q/D242N/E210Q

25 pAHLR209A/E210A/D96L

pAHLR209A/E210Q/E56Q

pAHL210Q/D242N/D254N

pAHL87Q/E210Q/D242N

30 **Lipase Variants II**

Example 6: Construction of a plasmid expressing the AL264->L269 variant of Humicola lanuginosa lipase.

35 **Linearization of plasmid pAHL:**

The circular plasmid pAHL was linearized with the restriction enzyme SphI in the following 50 μ l reaction mixture: 50 mM NaCl, 10 mM Tris-HCl, pH 7.9, 10 mM MgCl₂, 1 mM dithiothreitol, 1 μ g plasmid and 2 units of SphI. The digestion was carried out for 2 hours at 37°C. The reaction mixture was extracted with phenol (equilibrated with Tris-HCl, pH 7.5) and precipitated by adding 2 volumes of ice-cold 96% ethanol. After centrifugation and drying of the pellet, the linearized DNA was dissolved in 50 μ l H₂O and the concentration estimated on an agarose gel.

10

3-step PCR mutagenesis:

As shown in figure 4, 3-step mutagenisation involves the use of four primers:

15

Mutagenisation primer (=A):

5'-CAGGCGCGCCGCCACCCGAAGTACCATAG-3'

PCR Helper 1 (=B):

20 5'-GGTCATCCAGTCACTGAGACCCTCTACCTATTAAATCGGC-3'

PCR Helper 2 (=C): 5'-CCATGGCTTTCACGGTGTCT-3'

PCR Handle (=D): 5'-GGTCATCCAGTCACTGAGAC-3'

25 Helper 1 and helper 2 are complementary to sequences outside the coding region. All 3 steps were carried out in the following buffer containing: 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM TTP, 2.5 units Taq polymerase.

30

In step 1, 100 pmol primer A, 100 pmol primer B and 1 fmol linearized plasmid was added to a total of 100 μ l reaction mixture and 15 cycles consisting of 2 minutes at 95°C, 2 minutes at 37°C and 3 minutes at 72°C were carried out.

35

The concentration of the PCR product was estimated on an agarose gel. Then, step 2 is carried out. 0.6 pmol step 1 product and 1

fmol linearized plasmid was contained in a total of 100 μ l of the previously mentioned buffer and 1 cycle consisting of 5 minutes at 95°C, 2 minutes at 37°C and 10 minutes at 72°C was carried out.

5

To the step 2 reaction mixture, 100 pmol primer C and 100 pmol primer D is added (1 μ l of each) and 20 cycles consisting of 2 minutes at 95°C, 2 minutes at 37°C and 3 minutes at 72°C were carried out. This manipulation comprised step 3 in the mutagenisation procedure.

10

Isolation of mutated restriction fragment:

The product from step 3 was isolated from an agarose gel and re-dissolved in 20 μ l H₂O. Then, it was digested with the restriction enzymes BglII and BstXI in a total volume of 50 μ l with the following composition: 100 mM NaCl, 50 mM Tris-HCl, pH 7.9, 10 mM MgCl₂, 1 mM DTT, 10 units of BglII and 10 units of BstXI. Incubation was at 37°C for 2 hours. The 200 bp BglII/BstXI fragment was isolated from an agarose gel.

20

Ligation to expression vector pAHL:

The expression plasmid pAHL was cleaved with BglII and BstXI under conditions indicated above and the large fragment was isolated from an agarose gel. To this vector, the mutated fragment isolated above was ligated and the ligation mix was used to transform E.coli. The presence of the fragment was verified by cleavage of a plasmid preparation from a transformant with restriction enzymes. Sequence analysis was carried out on the double-stranded plasmid using the di-deoxy chain termination procedure developed by Sanger. The plasmid was named pAHLΔL264→L269 and is identical to pAHL, except for the deleted codons.

30

Example 7: Construction of plasmids expressing other variants of Humicola lipas .

35

The following mutants were constructed using the same method as described in example 6, with the exception that other restriction enzymes were used for digesting the PCR-product and the vector used for recloning of the mutated fragment. Plasmid names and primers used for the modifications are listed below.

	Plasmid name	Primer A sequence
	pAHLΔN247->D254	5'-TAGGTGCGCAGGGATCGGAATGTTAG GCTGGTTGCCCGCCGGTGGCATC-3'
10	pAHLE239* + I241* + D242*	5'-ATTGCCCGCCGGTGGCGCCTATCTTCA CGATATC-3'

Example 8: Construction of the lipase variant L206V by cassette mutagenesis:

Using the method outlined in example 6, the coding sequence on plasmid pAHL was modified to contain unique AvrII and MluI sites. The AvrII site was made by changing the G681 of the coding sequence to an adenosine. The MluI site was made by changing C759 to G and A762 to T. The new plasmid was named pAHL7 and encodes the same lipase as pAHL. Between the AvrII- and MluI-sites the following synthetically made linker was inserted (changes the Leu-codon to a Val-codon and deletes the ScaI-site for easy screening among transformants):

```

***
AvrII  CTAGGGTTCCGCCGCGCGAATTCGGTTACAGCCATTCT
      CCAAGGCGGCGCGCTTAAGCCAATGTCGGTAAGA
30      ArgValProProArgGluPheGlyTyrSerHisSer -
      205              210              216
      *
      AGCCCAGAATACTGGATCAAATCTGGAACCCTTGTCCTCCCGTCA      MluI
      TCGGGTCTTATGACCTAGTTTAGACCTTGGGAACAGGGGCAGTGC GC
35      SerProGluTyrTrpIleLysSerGlyThrLeuValProValThrArg
      217              220              225              230

```

The resulting plasmid was named pAHL206V, and is identical to pAHL, except for the changed bases.

5 Example 9: Construction of other lipase variants using cassette mutagenesis:

Other mutants constructed by cassette mutagenesis as described in example 8 are listed below. Other linkers were used for introducing the appropriate mutations.

10

Plasmid name

pAHL206A

pAHLF211V

pAHLF211A

15

pAHLDR209/E210

Lipase Variants III

20 Example 10: Construction of a plasmid expressing the D62C + E87C variant of Humicola lanuginosa lipase.

Linearization of plasmid pAHL:

25 The circular plasmid pAHL was linearized with the restriction enzyme SphI in the following 50 µl reaction mixture: 50 mM NaCl, 10 mM Tris-HCl, pH 7.9, 10 mM MgCl₂, 1 mM dithiothreitol, 1 µg plasmid and 2 units of SphI. The digestion was carried out for 2 hours at 37°C. The reaction mixture was extracted with phenol (equilibrated with Tris-HCl, pH 7.5) and precipitated by adding
30 2 volumes of ice-cold 96% ethanol. After centrifugation and drying of the pellet, the linearized DNA was dissolved in 50 µl H₂O and the concentration estimated on an agarose gel.

3-step PCR mutagenesis:

35

As shown in figure 4, 3-step mutagenisation involves the use of four primers:

Mutagenisation primer

(=A): 5'-ATTCCCGATCCAGTTACATATGGAACGAGAGCCACGGAAGCTTAGGACG
ATCAATTGTTTCGTGTTGTCGAGAGCAAGGAAGCCGGTGACACAGCCCCTC
CAGAGTC-3'

5

PCR Helper 1 (=B): 5'-GGTCATCCAGTCACTGAGACCCTCTACCTATTAAA-
TCGGC-3'

PCR Helper 2 (=C): 5'-CCATGGCTTTCACGGTGTCT-3'

10 PCR Handle (=D): 5'-GGTCATCCAGTCACTGAGAC-3'

Apart from altering two codons in the lipase coding region, primer A also introduces a silent mutation, thereby creating a HindIII-site between the codon-changes.

15

All 3 steps were carried out in the following buffer containing: 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM TTP, 2.5 units Taq polymerase.

20

In step 1, 100 pmol primer A, 100 pmol primer B and 1 fmol linearized plasmid was added to a total of 100 µl reaction mixture and 15 cycles consisting of 2 minutes at 95°C, 2 minutes at 37°C and 3 minutes at 72°C were carried out.

25

The concentration of the PCR product was estimated on an agarose gel. Then, step 2 is carried out. 0.6 pmol step 1 product and 1 fmol linearized plasmid was contained in a total of 100 µl of the previously mentioned buffer and 1 cycle consisting of 5
30 minutes at 95°C, 2 minutes at 37°C and 10 minutes at 72°C was carried out.

To the step 2 reaction mixture, 100 pmol primer C and 100 pmol primer D is added (1 µl of each) and 20 cycles consisting of 2
35 minutes at 95°C, 2 minutes at 37°C and 3 minutes at 72°C were carried out. This manipulation comprised step 3 in the mutagenisation procedure.

Isolation of mutated restriction fragment:

The product from step 3 was isolated from an agarose gel and re-dissolved in 20 μ l H₂O. Then, it was digested with the restriction enzymes BamHI and BstXI in a total volume of 50 μ l with the following composition: 100 mM NaCl, 50 mM Tris-HCl, pH 7.9, 10 mM MgCl₂, 1 mM DTT, 10 units of BamHI and 10 units of BstXI. Incubation was at 37°C for 2 hours. The 733 bp BamHI/BstXI fragment was isolated from an agarose gel.

10 Ligation to expression vector pAHL:

The expression plasmid pAHL was cleaved with BamHI and BstXI under conditions indicated above and the large fragment was isolated from an agarose gel. To this vector, the mutated fragment isolated above was ligated and the ligation mix was used to transform E.coli. The presence and orientation of the fragment was verified by cleavage of a plasmid preparation from a transformant with restriction enzymes. Sequence analysis was carried out on the double-stranded plasmid using the dideoxy chain termination procedure developed by Sanger. The plasmid was named pAHL62C/E87C and is identical to pAHL, except for the altered codons.

Example 11: Construction of plasmids expressing other variants of Humicola lipase.

25

The following mutants were constructed using the same method as described in example 10, except that other restriction enzymes were used for digesting the PCR-product and the vector used for recloning of the mutated fragment. Plasmid names and primers used for the modifications are listed below.

Plasmid name	Primer A sequence
pAHLG61C/E87C	5'-AAGATTCCCGATCCAACACTCTATGGAACGAGAGCCACGGAAG-CTTAGGACGATCAATTTGTTTCGTGTTGTGCGAGAGCAAGGAAGCCGG-TGACATCACACACTCCAGAGTCTTC-3'
pAHLI255T/L259T	5'-TAACCCGAAGTACCAAGTGTGCGCAGGAGTATCCGGAATGTTAG-3'

Example 12: Construction of the lipase variant L206V by cassette mutagenesis:

Using the method outlined in example 3, the coding sequence on
 5 plasmid pAHL was modified to contain unique AvrII and MluI
 sites. The AvrII site was made by changing the G681 of the
 coding sequence to an adenosine. The MluI site was made by
 changing C759 to G and A762 to T. The new plasmid was named
 pAHL7 and encodes the same lipase as pAHL. Between the AvrII-
 10 and MluI-sites the following synthetically made linker was
 inserted (changes the Leu-codon to a Val-codon and deletes the
 ScaI-site for easy screening among clones with the linker
 cloned):

```

15          ***
          CTAGGGTTCCGCCGCGCGAATTCGGTTACAGCCATTCT
          CCAAGGCGGCGCGCTTAAGCCAATGTCGGTAAGA
          ArgValProProArgGluPheGlyTyrSerHisSer -
          205          210          216
20          *
          AGCCCAGAATACTGGATCAAATCTGGAACCCTTGTCCTCCCGTCA
          TCGGGTCTTATGACCTAGTTTAGACCTTGGGAACAGGGGCAGTGCGC
          SerProGluTyrTrpIleLysSerGlyThrLeuValProValThrArg
          217          220          225          230
  
```

The resulting plasmid was named pAHL7206V, and is identical to pAHL, except for the changed bases.

Example 13: Construction of other lipase variants using cassette mutagenesis:

Other mutants constructed by cassette mutagenesis as described
 in example 3 are listed below. Other linkers were used for
 35 introducing the appropriate mutations.

Plasmid name

pAHL206T
pAHL206S
pAHL206A
pAHL206G
5 pAHLF211L
pAHLF211T
pAHLF211K

10 Example 14: Construction of lipase variants by combination of available mutants:

The following mutants were constructed by combining plasmid fragments of mutants constructed above. For example, pAHLG61C+E87C was constructed by isolating the HindIII
15 restriction fragment from pAHL62C+E87C (the primer used for the construction introduced a HindIII site between the two mutations) and inserting the fragment into pAHLG61C+N88C digested with HindIII (also introduced together with the mutations):
20 Plasmid
pAHL61C+E87C
pAHL206S+I255T+L259T

Example 15

25

Transformation of Aspergillus oryzae (general procedure)

100 ml of YPD (Sherman et al., Methods in Yeast Genetics, Cold Spring Harbor Laboratory, 1981) was inoculated with spores of A. oryzae and incubated with shaking for about 24 hours. The
30 mycelium was harvested by filtration through miracloth and washed with 200 ml of 0.6 M MgSO₄. The mycelium was suspended in 15 ml of 1.2 M MgSO₄, 10 mM NaH₂PO₄, pH = 5.8. The suspension was cooled on ice and 1 ml of buffer containing 120 mg of Novozym
35 234, batch 1687 was added. After 5 min., 1 ml of 12 mg/ml BSA (Sigma type H25) was added and incubation with gentle agitation continued for 1.5 - 2.5 hours at 37°C until a large number of

protoplasts was visible in a sample inspected under the microscope.

The suspension was filtered through miracloth, the filtrate
5 transferred to a sterile tube and overlaid with 5 ml of 0.6 M
sorbitol, 100 mM Tris-HCl, pH = 7.0. Centrifugation was
performed for 15 min. at 1000 g and the protoplasts were
collected from the top of the MgSO_4 cushion. 2 volumes of STC
(1.2 M sorbitol, 10 mM Tris-HCl, pH = 7.5, 10 mM CaCl_2) were
10 added to the protoplast suspension and the mixture was
centrifugated for 5 min. at 1000 g. The protoplast pellet was
resuspended in 3 ml of STC and repelleted. This was repeated.
Finally, the protoplasts were resuspended in 0.2 - 1 ml of STC.

100 μl of protoplast suspension was mixed with 5 - 25 μg of
15 p3SR2 (an *A. nidulans* amdS' gene carrying plasmid described in
Hynes et al., Mol. and Cel. Biol., Vol. 3, No. 8, 1430-1439,
Aug. 1983) in 10 μl of STC. The mixture was left at room
temperature for 25 min. 0.2 ml of 60% PEG 4000 (BDH 29576), 10
mM CaCl_2 and 10 mM Tris-HCl, pH = 7.5 was added and carefully
20 mixed (twice) and finally 0.85 ml of the same solution was added
and carefully mixed. The mixture was left at room temperature
for 25 min., spun at 2.500 g for 15 min. and the pellet was
resuspended in 2 ml of 1.2 M sorbitol. After one more
sedimentation the protoplasts were spread on minimal plates
25 (Cove, Biochem. Biophys. Acta 113 (1966) 51-56) containing 1.0
M sucrose, pH = 7.0, 10 mM acetamide as nitrogen source and 20
mM CsCl to inhibit background growth. After incubation for 4 -
7 days at 37°C spores were picked, suspended in sterile water
and spread for single colonies. This procedure was repeated and
30 spores of a single colony after the second reisolation were
stored as a defined transformant.

Example 16

35 Expression of the lipase variant D96L in *A. oryzae*

pAHL96L was transformed into A. oryzae IFO 4177 by cotransformation with p3SR2 containing the amdS gene from A. nidulans as described in example 15. Protoplasts prepared as described were incubated with a mixture of equal amounts of pAHL96L and p3SR2, approximately 5 µg of each were used. transformants which could use acetamide as sole nitrogen source were reisolated twice. After growth on YPD for three days, culture supernatants were analyzed using the assay for lipase activity described in example 16 (Purification of lipase variants of the invention). The best transformant was selected for further studies and grown in a 1 l shake-flask on 200 ml FG4 medium (3% soy meal, 3% maltodextrin, 1% peptone, pH adjusted to 7.0 with 4 M NaOH) for 4 days at 30°C. Under these conditions the transformant gave about 500 lipase units per ml of culture.

15

The other lipase variants were produced essentially as described above, using the general procedure described in example 15.

Example 17

20

Purification of lipase variants of the invention

Assay for lipase activity :

A substrate for lipase was prepared by emulsifying glycerine tributyrat (MERCK) using gum-arabic as emulsifier.

Lipase activity was assayed at pH 7 using pH stat method. One unit of lipase activity (LU/mg) was defined as the amount needed to liberate one micromole fatty acid per minute.

Step 1:- Centrifuge the fermentation supernatant, discard the precipitate. Adjust the pH of the supernatant to 7 and add gradually an equal volume of cold 96 % ethanol. Allow the mixture to stand for 30 minutes in an ice bath. Centrifuge and discard the precipitate.

35

Step 2:- Ion exchange chromatography. Filter the supernatant and apply on DEAE-fast flow (Pharmacia TM) column equilibrated with

- 50 mM tris-acetate buffer pH 7. Wash the column with the same buffer till absorption at 280 nm is lower than 0.05 OD. Elute the bound enzymatic activity with linear salt gradient in the same buffer (0 to 0.5 M NaCl) using five column volumes.
- 5 Pool the fractions containing enzymatic activity .

- Step 3:- Hydrophobic chromatography. Adjust the molarity of the pool containing enzymatic activity to 0.8 M by adding solid Ammonium acetate. Apply the enzyme on TSK gel Butyl- Toyopearl
- 10 650 C column (available from Tosoh Corporation Japan) which was pre-equilibrated with 0.8 M ammonium acetate. Wash the unbound material with 0.8 M ammonium acetate and elute the bound material with distilled water.
- 15 Step 4:- Pool containing lipase activity is diluted with water to adjust conductance to 2 mS and pH to 7. Apply the pool on High performance Q Sepharose (Pharmacia) column pre-equilibrated with 50 mM tris -acetate buffer pH 7. Elute the bound enzyme with linear salt gradient.

20

Example 18

The washing performance of lipase variants of the invention

- 25 The washing performance of Humicola lanuginosa lipase variants of the invention was evaluated on the basis of the enzyme dosage in mg of protein per litre according to OD₂₈₀ compared to the wild-type H. lanuginosa lipase.
- 30 Wash trials were carried out in 150 ml beakers placed in a thermostated water bath. The beakers were stirred with triangular magnetic rods.

The experimental conditions were as follows:

35

Method: 3 cycles with overnight drying between each cycle

Wash liquor: 100 ml per beaker
 Swatches: 6 swatches (3.5 x 3.5 cm) per beaker
 Fabric: 100% cotton, Test Fabrics style #400
 Stain: Lard coloured with Sudan red (0.75 mg dye/g of
 5 lard). 6 µl of lard heated to 70°C was applied
 to the centre of each swatch. After application
 of the stain, the swatches were heated in an
 oven at 75°C for 30 minutes. The swatches were
 then stored overnight at room temperature prior
 10 to the first wash.
 Detergent: LAS (Nansa 1169/P, 30% a.m.) 1.17 g/l
 AEO (Dobanol 25-7) 0.15 g/l
 Sodium triphosphate 1.25 g/l
 Sodium sulphate 1.00 g/l
 15 Sodium carbonate 0.45 g/l
 Sodium silicate 0.15 g/l
 pH: 10.2
 Lipase conc.: 0.075, 0.188, 0.375, 0.75 and 2.5 mg of lipase
 protein per litre
 20 Time: 20 minutes
 Temperature: 30°C
 Rinse: 15 minutes in running tap water
 Drying: overnight at room temperature (~20°C, 30-50% RH)
 Evaluation: after the 3rd wash, the reflectance at 460 nm
 25 was measured.

Results

Dose-response curves were compared for the lipase variants and
 30 the native H. lanuginosa lipase. The dose-response curves were
 calculated by fitting the measured data to the following
 equation:

$$\Delta R = \Delta R_{\max} \frac{C^{0.5}}{K + C^{0.5}} \quad (I)$$

35

where ΔR is the effect expressed in reflectance units
 C is the enzyme concentration (mg/l)

ΔR_{\max} is a constant expressing the maximum effect
 K is a constant; K^2 expresses the enzyme concentration
 at which half of the maximum effect is obtained.

- 5 Based on the characteristic constants ΔR_{\max} and K found for each lipase variant as well as the wild-type lipase, improvement factors were calculated. The improvement factor, defined as

$$f_{\text{improve}} = C_{\text{WT}}/C \quad (\text{II})$$

10

expresses the amount of lipase variant protein needed to obtain the same effect as that obtained with 0.25 mg/l of the reference wild-type protein (C_{WT}).

- 15 Thus, the procedure for calculating the improvement factor was as follows:

- 1) The effect of the wild-type protein at 0.25 mg/l ($\Delta R_{\text{wild-type}}$) was calculated by means of equation (I);
 20 2) the concentration of lipase variant resulting in the same effect as the wild-type at 0.25 mg/l was calculated by means of the following equation:

$$25 \quad C = (K_{(\text{variant})} \frac{\Delta R_{(\text{wild-type})}}{\Delta R_{\max(\text{variant})} - \Delta R_{(\text{wild-type})}})^2 \quad (\text{III})$$

- 3) the improvement factor was calculated by means of equation (II).

30

The results are shown in Table 1 below.

Table 1

	Variant	Improvement factor
5	D96L	4.4
	D111L	1.0
	E87A	1.0
	E56A	1.6
10	E56Q	2.6
	R209A	1.1
	D242N	1.7
	R209A+E210A	1.9
	R209A+E210A+D96L	2.8
15	E210Q+D242N+D254N	1.8
	R209A+E210A+D96L+E56Q	1.5
	L206A	1.0
20	L206V	1.6
	L206S	1.3
	F211L	1.0
	F211I	1.1
25	F211A	
	R209* + E210*	0.9
30		

It appears from Table 1 that the lipase variants R209A+E210A, E56Q and D96L have a considerably better wash performance than the wild-type lipase. This might possibly be ascribed to the decreased negative charge and increased hydrophobicity of these variants resulting in increased adsorption during washing and consequently higher activity during the drying phase. The performance of the lipase variants E87A, D111N and R209A is on a par with that of the wild-type enzyme.

Example 19

Increased Thermostability of Lipase Variants

The thermostability of selected variants of *H. lanuginosa* lipase has been examined by Differential Scanning Calorimetry (DSC). Using this technique, the thermal denaturation temperature, T_d ,

is determined by heating an enzyme solution at a constant programmed rate.

Experiments:

- 5 The Differential Scanning Calorimeter, MC-2D, from MicroCal Inc. was used for the investigations. 50 mM buffer solutions in was prepared at the following pH-values: 4 (acetate), 7 (TRIS-acetate), 10 (glycine). The enzyme concentration ranged between 0.6 - and 0.9 mg/ml, and a total volume of ca. 1.2 ml was used
10 for each experiment. All samples were heated from 5 'C to 95 'C at a scan rate of 90°C/hr..

Results:

- The results for the wild type and selected mutants are shown in
15 the table below.

20	No	Mutation	pH 4		pH 7		pH 10	
			Td	dTd	Td	dTd	Td	dTd
	WT	-	58.9	-	74.7	-	69.3	-
25	1	F211A	60.2	+1.3	75.8	+1.1	70.3	+1.0
	2	T267R	59.4	+0.5	75.7	+1.0	70.0	+0.7
	3	D111N	58.3	-0.6	75.6	+0.9	69.9	+0.6
30	4	F211L	57.8	-1.1	74.8	0.1	69.4	0.1

- Note: dTd denotes the the change in thermostability as a
35 result of the mutation.

Example 20

- 40 Storage stability of H. lanuginosa lipase variants in liquid detergent.

Several variants were tested in a model liquid detergent with the following composition:

45

		%	w/w
	Anionic	LAS	10
		AS	1
5		Soap	14
	Nonionic	AEO	13
	Solvent	1,2-propane diol	3
		Ethanol	5
	Buffer	TEA	6
10	Builder	Sodium citrate	1
	Neutr.agent	NaOH	2
	Stabilizer etc.	SXS	1
		Ca ²⁺	0,0025
		Phosphonate	0,4
15		Na ₂ SO ₄	0,2
	Water	add to 100%	
	pH	8 or 10	

20

1000 LU per gram of detergent was added and in some samples 0.025 AU/g (Alcalase®) was added. Samples were stored according to the following scheme (triplicate of each):

25

Storage temperature: -18°C 30°C

30

Detergent		
pH 8 , no protease	2 & 7 days	2 & 7 days
pH 8 , 0.025 AU/g		2 days
pH 10, no protease	7 days	7 days

35

Following this incubation the samples were analyzed according to the LU-method (Novo Nordisk AF 95.5).

Assuming that the decay of lipase activity follows a first order kinetic, the rate constant of the decay can be determined:

$$A(t) = A_0 \cdot \exp(-k \cdot t)$$

40 A(t) being the enzyme activity at time t, A₀ the initial activity and k the first order rate constant.

For the detergent containing protease a rate constant for the proteolysis can be calculated from

45
$$A(t) = A_0 \cdot \exp(-[k+k_p] \cdot t)$$

where k_p is the rate constant of proteolysis, and where k is calculated from the stability data determined in the detergent without protease.

- 5 In each experiment the wild-type H. lanuginosa lipase was included as a reference, and comparison of the variants with the wild-type is only done within an experiment in order to reduce the uncertainty of variation between experiments.
- Below the results are given, and the relative improvement of a
10 variant over the wild-type is given as:

$$IF_x = k_{wt}/k_x$$

- where IF means Improvement factor, k_{wt} is the rate constant of decay of the wild-type (at the given conditions) and k_x is the corresponding rate constant of the variant in question in the
15 same experiment.

IF expresses the relative improvement in half-life ($IF_x=2$ indicates that the half-life of variant x is twice as long as that of the wild-type in the same experiment).

- Based on an estimation of variations of replicates within an
20 experiment an $IF < 0.7$ or $IF > 1.3$ is considered significant.
The unit of k is $(\text{day})^{-1}$.

	Variant	Experi- ment no.	pH 8 no prot.		pH 8 +Alcalase		pH 10 no prot.	
			k ^a	IF ^a)	k _p	IF	k	IF
5	Wildtype	3	0.02		0.48		0.19	
		5	0.02		0.40		0.16	
		6	0.00		0.34		0.09	
		7	0.01		0.52		0.22	
		8	0.01		0.50		0.09	
10		a	0.01		0.52		0.07	
		b	0.01		0.52		0.07	
15	D96N	3	0.00		0.21	2.3	0.15	1.3
		5	0.02		0.26	1.6	n.d.	
	D111N	3	0.00		0.50	1.0	0.16	1.2
		5	0.02		0.31	1.3	0.13	1.2
20	E56Q	3	0.01		0.22	2.2	0.14	1.4
		6	0.01		0.17	2.0	0.08	1.2
	D96L	6	0.01		0.17	2.0	0.08	1.2
		7	0.00		0.23	2.3	0.09	2.6
25	R209A/E210A/D96L	7	0.02		0.36	1.4	0.10	2.3
		7	0.02		0.49	1.0	n.d.	
30	F211L	6	0.02		0.41	0.8	0.08	1.1
		8	0.02		1.4	0.4	0.06	1.5
	F211T	8	0.02		1.4	0.4	0.06	1.5
		8	0.01		0.58	0.9	0.02	3.1
35	F211A	8	0.01		0.58	0.9	0.02	3.1
		8	0.02		1.4	0.4	0.08	1.2
	F211I	8	0.02		1.4	0.4	0.08	1.2
		8	0.02		1.4	0.4	0.08	1.2

40 ^a)k in the detergent at pH 8 is in all cases very low, and due to the short storage time (7 days, approx. 90% residual activity) it is not determined very accurately. Hence the IF is not calculated.

45

In conclusion a number of the tested variants had improved resistance to proteolytic degradation, and they almost all had improved resistance to alkaline conditions.

Example 21**Specific activity**

A higher specific activity (amounts of substrate molecules cleaved pr. unit time pr. unit amount) than the wild-type (wt) was measured for the lipase variants shown below. This means that these lipases have a superior performance of hydrolysing the actual substrate.

The lipases were fermented and purified in the same way. The purified lipases were tested in a standard LU assay (Analytical method, internal NOVO NORDISK number AF 95/6-GB 1991.02.07). The sample was analysed twice, and the mean values are tabulated. The amount of protein was estimated by optical density measurements on a Shimadzu spectrofotometer, using the wavelength 280 nm. The sample was regarded as pure when the proportional value of OD280 divided by OD260 was greater than 1.6, together with a single band SDS-polyacrylamid gel electroforesis.

20

25

30

Humicola lanuginosa	Specific activity LU/OD280
D111N	4290*
E56A	4890*
L206V	4750
F211T	4550
F211V	5060
F211I	6686
R209*/E210*	6686
R209A/E210A/D96L	4818
wt	3790

* only tested once

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Novo Nordisk A/S
- (ii) TITLE OF INVENTION: Lipase Variants
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Novo Nordisk A/S
 - (B) STREET: Novo Alle
 - (C) CITY: Bagsvaerd
 - (E) COUNTRY: Denmark
 - (F) ZIP: 2880
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: DK 2196/90
 - (B) FILING DATE: 13-SEP-1990
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: DK 2194/90
 - (B) FILING DATE: 13-SEP-1990
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: DK 2195/90
 - (B) FILING DATE: 13-SEP-1990
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Thalsoe-Madsen, Birgit
 - (C) REFERENCE/DOCKET NUMBER: 3520.204-WO
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: +45 4444 8888
 - (B) TELEFAX: +45 4449 3256
 - (C) TELEX: 37304

(2) INFORMATION FOR SEQ ID NO:1:

50

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 918 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Humicola lanuginosa*

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..873

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG	AGG	AGC	TCC	CTT	GTG	CTG	TTC	TTT	GTC	TCT	GCG	TGG	ACG	GCC	TTG	48
Met	Arg	Ser	Ser	Leu	Val	Leu	Phe	Phe	Val	Ser	Ala	Trp	Thr	Ala	Leu	
1				5					10					15		
GCC	AGT	CCT	ATT	CGT	CGA	GAG	GTC	TCG	CAG	GAT	CTG	TTT	AAC	CAG	TTC	96
Ala	Ser	Pro	Ile	Arg	Arg	Glu	Val	Ser	Gln	Asp	Leu	Phe	Asn	Gln	Phe	
			20					25					30			
AAT	CTC	TTT	GCA	CAG	TAT	TCT	GCA	GCC	GCA	TAC	TGC	GGA	AAA	AAC	AAT	144
Asn	Leu	Phe	Ala	Gln	Tyr	Ser	Ala	Ala	Ala	Tyr	Cys	Gly	Lys	Asn	Asn	
			35				40					45				
GAT	GCC	CCA	GCT	GGT	ACA	AAC	ATT	ACG	TGC	ACG	GGA	AAT	GCC	TGC	CCC	192
Asp	Ala	Pro	Ala	Gly	Thr	Asn	Ile	Thr	Cys	Thr	Gly	Asn	Ala	Cys	Pro	
	50					55					60					
GAG	GTA	GAG	AAG	GCG	GAT	GCA	ACG	TTT	CTC	TAC	TCG	TTT	GAA	GAC	TCT	240
Glu	Val	Glu	Lys	Ala	Asp	Ala	Thr	Phe	Leu	Tyr	Ser	Phe	Glu	Asp	Ser	
65						70				75				80		
GGA	GTG	GGC	GAT	GTC	ACC	GGC	TTC	CTT	GCT	CTC	GAC	AAC	ACG	AAC	AAA	288
Gly	Val	Gly	Asp	Val	Thr	Gly	Phe	Leu	Ala	Leu	Asp	Asn	Thr	Asn	Lys	
				85				90					95			
TTG	ATC	GTC	CTC	TCT	TTC	CGT	GGC	TCT	CGT	TCC	ATA	GAG	AAC	TGG	ATC	336
Leu	Ile	Val	Leu	Ser	Phe	Arg	Gly	Ser	Arg	Ser	Ile	Glu	Asn	Trp	Ile	
			100					105					110			
GGG	AAT	CTT	AAC	TTC	GAC	TTG	AAA	GAA	ATA	AAT	GAC	ATT	TGC	TCC	GGC	384
Gly	Asn	Leu	Asn	Phe	Asp	Leu	Lys	Glu	Ile	Asn	Asp	Ile	Cys	Ser	Gly	
		115					120					125				
TGC	AGG	GGA	CAT	GAC	GGC	TTC	ACT	TCG	TCC	TGG	AGG	TCT	GTA	GCC	GAT	432
Cys	Arg	Gly	His	Asp	Gly	Phe	Thr	Ser	Ser	Trp	Arg	Ser	Val	Ala	Asp	
	130					135					140					

51

```

ACG TTA AGG CAG AAG GTG GAG GAT GCT GTG AGG GAG CAT CCC GAC TAT 480
Thr Leu Arg Gln Lys Val Glu Asp Ala Val Arg Glu His Pro Asp Tyr
145                      150                      155                      160

CGC GTG GTG TTT ACC GGA CAT AGC TTG GGT GGT GCA TTG GCA ACT GTT 528
Arg Val Val Phe Thr Gly His Ser Leu Gly Gly Ala Leu Ala Thr Val
                      165                      170                      175

GCC GGA GCA GAC CTG CGT GGA AAT GGG TAT GAT ATC GAC GTG TTT TCA 576
Ala Gly Ala Asp Leu Arg Gly Asn Gly Tyr Asp Ile Asp Val Phe Ser
                      180                      185                      190

TAT GGC GCC CCC CGA GTC GGA AAC AGG GCT TTT GCA GAA TTC CTG ACC 624
Tyr Gly Ala Pro Arg Val Gly Asn Arg Ala Phe Ala Glu Phe Leu Thr
                      195                      200                      205

GTA CAG ACC GGC GGA ACA CTC TAC CGC ATT ACC CAC ACC AAT GAT ATT 672
Val Gln Thr Gly Gly Thr Leu Tyr Arg Ile Thr His Thr Asn Asp Ile
                      210                      215                      220

GTC CCT AGA CTC CCG CCG CGC GAA TTC GGT TAC AGC CAT TCT AGC CCA 720
Val Pro Arg Leu Pro Pro Arg Glu Phe Gly Tyr Ser His Ser Ser Pro
225                      230                      235                      240

GAG TAC TGG ATC AAA TCT GGA ACC CTT GTC CCC GTC ACC CGA AAC GAT 768
Glu Tyr Trp Ile Lys Ser Gly Thr Leu Val Pro Val Thr Arg Asn Asp
                      245                      250                      255

ATC GTG AAG ATA GAA GGC ATC GAT GCC ACC GGC GGC AAT AAC CAG CCT 816
Ile Val Lys Ile Glu Gly Ile Asp Ala Thr Gly Gly Asn Asn Gln Pro
                      260                      265                      270

AAC ATT CCG GAT ATC CCT GCG CAC CTA TGG TAC TTC GGG TTA ATT GGG 864
Asn Ile Pro Asp Ile Pro Ala His Leu Trp Tyr Phe Gly Leu Ile Gly
                      275                      280                      285

ACA TGT CTT TAGTGGCCGG CGCGGCTGGG TCCGACTCTA GCGAGCTCGA GATCT 918
Thr Cys Leu
290

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 291 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Arg Ser Ser Leu Val Leu Phe Phe Val Ser Ala Trp Thr Ala Leu
 1              5              10              15

Ala Ser Pro Ile Arg Arg Glu Val Ser Gln Asp Leu Phe Asn Gln Phe

```

52

[illegible]

5

CLAIMS

1. A lipase variant of a parent lipase comprising a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule, wherein the electrostatic charge and/or hydrophobicity of a lipid contact zone comprising residues located within the part of the lipase structure containing the active serine residue, which residues may participate in the interaction with the substrate at or during hydrolysis, has been changed by deleting or substituting one or more negatively charged amino acid residues by neutral or positively charged amino acid residue(s), and/or by substituting one or more neutral amino acid residues by positively charged amino acid residue(s), and/or by deleting or substituting one or more hydrophilic amino acid residues by hydrophobic amino acid residue(s).
2. A lipase variant according to claim 1, wherein one or more glutamic acid aspartic acid residues of said lipid contact zone are substituted by glutamine, asparagine, alanine, leucine, valine, serine, threonine, lysine, or arginine.
3. A lipase variant according to any of claims 1-2, wherein the parent lipase is a microbial lipase.
4. A lipase variant according to claim 3, wherein the parent lipase is a fungal lipase.
5. A lipase variant according to claim 4, wherein the parent lipase is derived from a strain of Humicola, or Rhizomucor.
6. A lipase variant according to claim 5, wherein the parent lipase is a Rhizomucor miehei lipase.

40

7. A lipase variant according to claim 6, wherein one or more amino acid residues are substituted as follows:

D91N,K,R,A,V,L,S,T;

D256N,K,R,A,V,L,S,T;

5 D226N,K,R,A,V,L,S,T;

D61N,K,R,A,V,L,S,T;

D113N,K,R,A,V,L,S,T;

E201Q,K,R,A,V,L,S,T;

D243N,K,R,A,V,L,S,T.

10

8. A lipase variant according to claim 5, wherein the parent lipase is a Humicola lanuginosa lipase.

9. A lipase variant according to claim 8, wherein one or more amino acid residues are substituted as follows:

15 E87Q,K,R,A,N,T,S,L,V;

D254N,K,R,A,Q,T,S,L,V;

D242N,K,R,A,Q,T,S,L,V;

E210Q,K,R,A,N,T,S,L,V;

20 E56Q,K,R,A,N,T,S,L,V;

D96N,K,R,A,Q,T,S,L,V;

D111N,K,R,A,Q,T,S,L,V;

D62A,Q,N,T,S,K,R,L,V;

E219A,Q,N,T,S,K,R,L,V;

25 E234A,Q,N,T,S,K,R,L,V;

E57A,Q,N,T,S,K,R,L,V

E99A,Q,N,T,S,K,R,L,V;

D27A,Q,N,T,S,K,R,L,V; or

E239A,Q,N,T,S,K,R,L,V.

30

10. A lipase variant according to claim 9, wherein one or more amino acid residues are substituted as follows:

E87Q + D254N + D242N + E210Q;

E87Q + D254N + E210Q;

35 D96N + E87Q + D254N;

R209A + E210A.

11. A lipase variant according to claim 8, wherein one or more amino acid residues are substituted as follows
- T267K,R;
S85K,R;
5 T226K,R;
N88K,R;
N92K,R;
I255K,R;
I202K,R
10 L206K,R;
L259K,R;
V203K,R; or
L227K,R
- 15 12. A lipase variant according to claim 4, wherein the parent lipase is a yeast lipase.
13. A lipase variant according to claim 12, wherein the parent lipase is derived from a strain of Candida.
- 20 14. A lipase variant according to claim 3, wherein the parent lipase is a bacterial lipase.
15. A lipase variant according to claim 14, wherein the parent
25 lipase is derived from a strain of Pseudomonas.
16. A lipase variant comprising a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule,
30 said lipase variant being characterized by substitution, deletion, or insertion of one or more amino acid residues at the position of one or more of the amino acid residues constituting the sequence of the lipid contact zone comprising residues located within the part of the lipase structure containing the
35 active serine residue, which residues participate in the interaction with the substrate at or during hydrolysis so as to change the surface conformation of said lipid contact zone.

17. A lipase variant according to claim 16, wherein one or more amino acid residues are substituted by one or more other, less bulky amino acid residues.
- 5 18. A lipase variant according to claim 17, wherein one or more amino acid residues are substituted by valine, threonine, serine, glycine, or alanine.
19. A lipase variant according to claim 16, wherein one or more
10 amino acid residues forming part of loop sequences in the lipid contact zone are deleted.
20. A lipase variant according to claim 19, wherein 2-8, in particular 2-6 amino acid residues are deleted from one or more
15 loop sequences in the lipid contact zone.
21. A lipase variant according to any of claims 16-20, wherein the parent lipase is a microbial lipase.
- 20 22. A lipase variant according to claim 21, wherein the parent lipase is a fungal lipase.
23. A lipase variant according to claim 22, wherein the parent lipase is derived from a strain of Humicola or Rhizomucor.
- 25 24. A lipase variant according to claim 23, wherein the parent lipase is a Rhizomucor miehei lipase.
25. A lipase variant according to claim 24, wherein one or more
30 amino acid residues are substituted as follows:
I204V,A,T,S,G;
L208V,A,T,S,G;
F213V,A,T,S,G; or
I254V,A,T,S,G

26. A lipase variant according to claim 24, wherein one or more amino acid residues are deleted at one or more of the following positions: 82-113, 211-215, 235-243, 245-269 or 264-269.

- 5 27. A lipase variant according to claim 26, which is modified as follows:

N264* + T265* + G266* + L267* + C268* + T269* + C22T.

28. A lipase variant according to claim 26, wherein the
10 following amino acid residues are deleted:

F213* + F215*;

D238* + L239* + E240* + D243*; or

F251* + T252* + S247*

- 15 29. A lipase variant according to claim 23, wherein the parent lipase is a Humicola lanuginosa lipase.

30. A lipase variant according to claim 29, wherein one or more amino acid residues are substituted as follows:

- 20 I202V,A,T,S,G;

L206V,A,T,S,G;

F211V,A,T,S,G,I; or

I255V,A,T,S,G

- 25 31. A lipase variant according to claim 29, wherein the one or more amino acid residues are deleted at one or more of the following positions: 84-112, 209-213, 238-245, 247-254 or 264-269.

- 30 32. A lipase variant according to claim 31, which is modified as follows:

L264* + I265* + G266* + T267* + C268* + L269* + C22T.

33. A lipase variant according to claim 31, wherein the
35 following amino acid residues are deleted:

R209* + E210*;

F211* + Y213*;

D242* + E239* + I241*; or
N247* + D254*

34. A lipase variant according to claim 21, wherein the parent
5 lipase is a yeast lipase.

35. A lipase variant according to claim 34, wherein the parent
lipase is derived from a strain of Candida.

10 36. A lipase variant according to claim 21, wherein the parent
lipase is a bacterial lipase.

37. A lipase variant according to claim 36, wherein the parent
lipase is derived from a strain of Pseudomonas.

15

38. A lipase variant of a type comprising (i) a trypsin-like
catalytic triad including an active serine located in a
predominantly hydrophobic, elongated binding pocket of the
lipase molecule and (ii) a surface loop structure which covers
20 the active serine when the lipase is in inactive form and which
changes its conformation when the lipase is activated so as to
make the active serine accessible to a lipid substrate, the loop
structure having a predominantly hydrophobic inner surface
facing the binding pocket and a predominantly hydrophilic outer
25 surface, said lipase variant being characterized by
substitution, deletion or insertion of one or more amino acid
residues at the position of one or more of the amino acid
residues constituting the sequence of the loop structure and/or
constituting the sequence of the lipid contact zone comprising
30 residues located within the part of the lipase structure
containing the active serine residue, which residues participate
in either shifting the surface loop structure or the interaction
which the substrate at or during hydrolysis.

35 39. A lipase variant according to claim 38, wherein at least one
amino acid residue of the loop structure is substituted by
cysteine, and wherein at least one other amino acid residue is

substituted by cysteine, the two cysteine residues being so positioned relative to each other as to form a disulphide bond.

40. A lipase variant according to claim 38 or 39, wherein the
5 parent lipase is a microbial lipase.

41. A lipase variant according to any of claims 38-40, wherein the parent lipase is a fungal lipase.

10 42. A lipase variant according to claim 41, wherein the parent lipase is derived from a strain of Humicola or Rhizomucor.

43. A lipase variant according to claim 42, wherein the parent lipase is a Rhizomucor miehei lipase.

15

44. A lipase variant according to claim 43, wherein one or more amino acid residues are substituted as follows:

S114C + A90C;

R86C + D61C;

20 S84C + D61C;

N87C + D61C;

Y60C + R78C; or

Y60C + N87C

25 45. A lipase variant according to claim 43, wherein one or more amino acid residues are substituted as follows:

I204V,T,S,A,G;

L208V,T,S,A,G;

V254V,T,S,A,G;

30 L255V,T,S,A,G;

L258V,T,S,A,G;

L267V,T,S,A,G;

F94L,T,K; or

F213L,T,K

35

46. A lipase variant according to claim 43, which comprises the following amino acid substitutions:

I204T + L255T + L267T; or
L208T + V254T + L258T

47. A lipase variant according to claim 42, wherein the parent
5 lipase is a Humicola lanuginosa lipase.

48. A lipase variant according to claim 47, wherein one or more
amino acid residues are substituted as follows:

G61C + N88C;
10 G61C + E87C;
D62C + E87C;
D62C + S85C;
D62C + N88C; or
S116C + G91C

15

49. A lipase variant according to claim 47, wherein one or more
amino acid residues are substituted as follows:

L93V,T,S,A,G;
I90V,T,S,A,G;
20 I86V,T,S,A,G;
I202V,T,S,A,G;
L206V,T,S,A,G;
I255V,T,S,A,G;
L259V,T,S,A,G;
25 I265V,T,S,A,G;
F95L,T,K; or
F211L,T,K

50. A lipase variant according to claim 49, wherein one or more
30 amino acid residues are substituted as follows:

F95K;
I86T;
I90T;
I255T;
35 L259T;
L206T; or
L206T + I255T + L259T

51. A lipase variant according to claim 40, wherein the parent lipase is a yeast lipase.
52. A lipase variant according to claim 51, wherein the parent
5 lipase is derived from a strain of Candida.
53. A lipase variant according to claim 40, wherein the parent lipase is a bacterial lipase.
- 10 54. A lipase variant according to claim 53, wherein the parent lipase is derived from a strain of Pseudomonas.
55. A DNA construct comprising a DNA sequence encoding a lipase variant according to any of claims 1-54.
- 15 56. A recombinant expression vector which carries a DNA construct according to claim 55.
57. A cell which is transformed with a DNA construct according
20 to claim 55 or a vector according to claim 56.
58. A cell according to claim 57 which is a fungal cell, e.g. belonging to the genus Aspergillus, such as A. niger, A. oryzae, or A. nidulans; a yeast cell, e.g. belonging to a strain of
25 Saccharomyces, such as S. cerevisiae, or a methylotrophic yeast from the genera Hansenula, such as H. polymorpha, or Phichia, such as P. pastoris; or a bacterial cell, e.g. belonging to a strain of Bacillus, such as B. subtilis, or B. lentus.
- 30 59. A cell according to claim 57 which is a plant cell, e.g. belonging to the Solanaceae, such as Solanum tuberosum, or Nicotiana tabacum.
60. A plant comprising a cell according to claim 59.
- 35 61. A method of producing a lipase variant according to any of claims 1-54, wherein a cell according to any of claims 57-59, or

a plant according to claim 60 is cultured or grown under conditions conducive to the production of the lipase variant, and the lipase variant is subsequently recovered from the culture or plant.

5

62. A detergent additive comprising a lipase variant according to any of claims 1-54, optionally in the form of a non-dusting granulate, stabilised liquid or protected enzyme.

10 63. A detergent additive according to claim 62 which contains 0.02-200 mg of enzyme protein/g of the additive.

64. A detergent additive according to claim 62 or 63 which additionally comprises another enzyme such as a protease,
15 amylase, peroxidase and/or cellulase.

65. A detergent composition comprising a lipase variant according to any of claims 1-54.

20 66. A detergent composition according to claim 65 which additionally comprises another enzyme such as a protease, amylase, peroxidase and/or cellulase.

1/9




Fig. 1a

2/9




Fig. 1b

3/9




Fig. 2a

4/9




Fig. 2b

5/9




Fig. 3

6/9




Fig. 4

7/9




Fig. 5

8/9




Fig. 6

9/9







Fig. 7

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 91/00271

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 12 N 9/20, 15/55, C 11 D 3/386, C 12 N 5/14																	
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">IPC5</td> <td style="padding: 5px;">C 12 N; C 11 D</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such Documents are Included in Fields Searched⁸</div> <p style="padding: 5px;">SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	C 12 N; C 11 D											
Classification System	Classification Symbols																
IPC5	C 12 N; C 11 D																
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category *</th> <th style="width: 65%; border-bottom: 1px solid black;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 25%; border-bottom: 1px solid black;">Relevant to Claim No.¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">P,X</td> <td style="padding: 5px;">EP, A1, 0407225 (UNILEVER PLC) 9 January 1991, see abstract --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,3,14-16,21,36-37,55-66</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">EP, A2, 0375102 (THE CLOROX COMPANY) 27 June 1990, see especially claim 11 Table II --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,3,14-17,21,36-37,55-66</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">EP, A1, 0305216 (NOVO INDUSTRI A/S) 1 March 1989, see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-66</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Dialog Information Services, File 154, Medline 85-92, Dialog accession no. 07295905, Davis RC et al: "Hepatic lipase: site-directed mutagenesis of a serine residue important for catalytic activity", J Biol Chem, Apr 15 1990, 265 (11) p 6291-5 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,3,16,55-66</td> </tr> </table>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	P,X	EP, A1, 0407225 (UNILEVER PLC) 9 January 1991, see abstract --	1,3,14-16,21,36-37,55-66	X	EP, A2, 0375102 (THE CLOROX COMPANY) 27 June 1990, see especially claim 11 Table II --	1,3,14-17,21,36-37,55-66	A	EP, A1, 0305216 (NOVO INDUSTRI A/S) 1 March 1989, see the whole document --	1-66	X	Dialog Information Services, File 154, Medline 85-92, Dialog accession no. 07295905, Davis RC et al: "Hepatic lipase: site-directed mutagenesis of a serine residue important for catalytic activity", J Biol Chem, Apr 15 1990, 265 (11) p 6291-5 --	1,3,16,55-66
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
P,X	EP, A1, 0407225 (UNILEVER PLC) 9 January 1991, see abstract --	1,3,14-16,21,36-37,55-66															
X	EP, A2, 0375102 (THE CLOROX COMPANY) 27 June 1990, see especially claim 11 Table II --	1,3,14-17,21,36-37,55-66															
A	EP, A1, 0305216 (NOVO INDUSTRI A/S) 1 March 1989, see the whole document --	1-66															
X	Dialog Information Services, File 154, Medline 85-92, Dialog accession no. 07295905, Davis RC et al: "Hepatic lipase: site-directed mutagenesis of a serine residue important for catalytic activity", J Biol Chem, Apr 15 1990, 265 (11) p 6291-5 --	1,3,16,55-66															
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> * Special categories of cited documents:¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents:¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family													
* Special categories of cited documents:¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family																
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="padding: 5px;">13th February 1992</td> <td style="text-align: center; padding: 5px;">1992 -02- 14</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; padding: 5px;">SWEDISH PATENT OFFICE</td> <td style="text-align: center; padding: 5px;">  Mikael G:son Bergstrand </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	13th February 1992	1992 -02- 14	International Searching Authority	Signature of Authorized Officer	SWEDISH PATENT OFFICE	 Mikael G:son Bergstrand							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
13th February 1992	1992 -02- 14																
International Searching Authority	Signature of Authorized Officer																
SWEDISH PATENT OFFICE	 Mikael G:son Bergstrand																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	Dialog Information Services, File 154, Medline 85-92, Dialog accession no. 07295773, Semenkovich CF et al: "In vitro expression and site-specific mutagenesis of the cloned human lipoprotein lipase gene. Potential N-linked glycosylation site asparagine 43 is important for both enzyme activity and secretion" J Biol Chem Apr 5 1990, 265 (10) p 5429-33 ---	1,3,16, 55-66
X	Dialog Information Services, File 357, Biotechnology abstracts, Dialog accession no. 077832, Poulou A J: "Alteration of substrate specificity of a lipase by site specific mutagenesis - Pseudomonas enzyme (conference abstract)", Abstr.Pap.Am.Chem.Soc. (195 Meet BTEC47) 1988 ---	1,3,16, 55-66
A	NATURE, Vol. 343, 1990 Leo Brady et al: "A serine protease triad forms the catalytic centre of a triacylglycerol lipase", see page 767 - page 770 ---	1-66
A	NATURE, Vol. 343, 1990 F.K. Winkler et al: "Structure of human pancreatic lipase", see page 771 - page 774 -----	1-66

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers....., because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers....., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

See attached sheet!

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims. It is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☒ No protest accompanied the payment of additional search fees.

Claims 1-15 completely, 55-66 partially.

A lipase variant, where the electrostatic charge and/or the hydrophobicity of the lipid contact zone has been changed.

claims 16-37 completely, 55-66 partially.

A lipase variant, where the surface conformation of the lipid contactzone has been changed

claims 38-54 completely 55-66 partially.

A lipase variant supplied with a surface loop structure, which covers the active serine when the lipase is inactive, and which changes its conformation when the lipase is activated so as to make the active serine accessible to a lipid substrate.

These three categories of lipase variants are not considered have enough technical relationship so as to form a single inventive concept, particularly since it is known by EP,A2, 375 102 to change certain aminoacid residues of a lipase from Pseudomonas putida.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/DK 91/00271

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the Swedish Patent Office EDP file on 30/11/91
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0407225	91-01-09	WO-A- 91/00910	91-01-24
EP-A2- 0375102	90-06-27	JP-A- 2225599	90-09-07
EP-A1- 0305216	89-03-01	JP-A- 1157383	89-06-20